Business Context and Reporting Period
This Form 6-K filing by Akari Therapeutics Plc, dated September 14, 2022, reports on a definitive agreement entered into on September 12, 2022, for a registered direct offering and a concurrent private placement. The transaction involves the issuance of American Depositary Shares (ADSs) and warrants to healthcare-focused institutional investors, accredited investors, and certain existing investors, including Executive Chairman Dr. Ray Prudo.
Key Financial Metrics
- Gross Proceeds: Approximately $12.84 million from the sale of 15,100,000 ADSs at $0.85 per ADS.
- Placement Fees: A cash fee of 7% of the aggregate purchase price, plus up to $75,000 in expense reimbursement and a $50,000 non-accountable expense allowance payable to A.G.P./Alliance Global Partners.
- Warrant Issuance:
- Series A Warrants: Exercisable for up to 15,100,000 ADSs at $0.85 per ADS; expire two years after issuance.
- Series B Warrants: Exercisable for up to 15,100,000 ADSs at $0.85 per ADS; expire seven years after issuance.
- Ownership Blockers: Holders are restricted from exercising warrants to own more than 4.99% (or 9.99% at option) of outstanding shares immediately after exercise.
Note: This filing does not provide specific data on revenue, net profit, operating cash flow, margins, or total debt levels.
Material Changes
The primary material change is the dilution of existing shareholders through the issuance of 15,100,000 new ADSs and the creation of 30,200,000 warrant shares (15.1 million Series A and 15.1 million Series B). The filing does not provide comparative financial data against prior periods to quantify changes in operational metrics.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The Company expects the offering to close on or about September 14, 2022, subject to customary closing conditions. Proceeds are intended to fund operations, though specific allocation details are not provided in this text.
Risks and Contingencies: The filing includes a cautionary note regarding forward-looking statements and highlights significant risks, including:
- Need for additional capital to fund operations and ability to continue as a going concern.
- Uncertainties regarding cash flows and meeting working capital needs.
- Regulatory approval risks for product candidates, specifically nomacopan.
- Clinical trial uncertainties, including patient enrollment difficulties and unexpected costs.
- Intellectual property enforcement risks and manufacturing supply chain dependencies.
- Impact of the COVID-19 pandemic.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting placement fees and expenses.
- Confirm the effective date of the Form F-1 registration statement for the resale of warrant shares (required within 60 days of closing).
- Review the Company's most recent Form 20-F for detailed cash burn rates and runway analysis given the "going concern" risk disclosure.
- Assess the dilution impact of the 30.2 million warrant shares relative to the current outstanding share count.
- Monitor upcoming regulatory milestones for nomacopan to evaluate the necessity of future capital raises.